Osteoarthritis. Polyarthrosis, unspecified Generalized osteoarthritis NOS
Conditions
Interventions
Intervention 1: Intervention Group: Prescription of Crocina drug daily at dose of 15 milligram for 4 months. Intervention 2: Control Group: Prescription of placebo daily at dose of 15 milligram for 4
Treatment - Drugs
Placebo
Intervention Group: Prescription of Crocina drug daily at dose of 15 milligram for 4 months.
Control Group: Prescription of placebo daily at dose of 15 milligram for 4 months.
Sponsors
Research Chancellor, Mashhad University of Medical Sciences
Eligibility
Sex/Gender
All
Age
40 Years to 75 Years
Inclusion criteria
Inclusion criteria: Inclusion Criteria: Osteoarthritis patients aged 40 to 75; Patients with the severity of joint damage between grade 2 and grade 3 based on radiographic images; Patients with no history of joint surgery; Patients with no history of injury, no diabetic disorders, no rheumatism, no kidney disease, no osteonecrosis and gout; Patients with no long history of anti-inflammatory drugs consumption; Patients having no insufferable jobs; Patients with the Body Mass Index (BMI) of 30 or less. Exclusion Criteria: Osteoarthritis patients aged less than 40 and more than 75; Patients with the severity of joint damage of the in grade 1 and grade 4 based on radiographic images; Patients with history of joint surgery; Patients with history of injury, diabetic disorders, rheumatism, kidney disease, osteonecrosis and gout; Patients with long history of anti-inflammatory drugs consumption; Patients having insufferable jobs; Patients with a BMI of 30 or more.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Inflammation. Timepoint: Before The Intervention and 4 months after. Method of measurement: Visual.;Pain. Timepoint: Before The Intervention and 4 months after. Method of measurement: Visual.;Osteoarthritis. Timepoint: Before The Intervention and 4 months after. Method of measurement: Visualization and gradation 1 to 4.;Crocin. Timepoint: Four months after the intervention. Method of measurement: International units per millilitre.;Interleukin-4. Timepoint: Before the intervention and 4 months after. Method of measurement: Picograms per millilitre using ELISA Assay.;Interleukin-10. Timepoint: Before the intervention and 4 months after. Method of measurement: Picograms per millilitre using ELISA Assay.;Interleukin-1ß. Timepoint: Before the intervention and 4 months after. Method of measurement: Picograms per millilitre using ELISA Assay.;TGF-ß. Timepoint: Before the intervention and 4 months after. Method of measurement: Picograms per millilitre using ELISA Assay.;Interleukin-17. Timepoint: Before the intervention and 4 months after. Method of measurement: Picograms per millilitre using ELISA Assay.;CD127. Timepoint: Before the intervention and 4 months after. Method of measurement: Frequency of desired cells using Fow Cytometry Technique.;T-bet transcription factor. Timepoint: Before the intervention and 4 months after. Method of measurement: The copy number of desired gene using RT-PCR Assay.;FOXP3 transcription factor. Timepoint: Before the intervention and 4 months after. Method of measurement: The copy number of desired gene using RT-PCR Assay.;GATA3 transcription factor. Timepoint: Before the intervention and 4 months after. Method of measurement: The copy number of desired gene using RT-PCR Assay.;ROR-?t transcription factor. Timepoint: Before the intervention and 4 months after. Method of measurement: The copy number of desired gene using RT-PCR Assay.;Regulatory T Cells. Timepoint: Before the intervention and 4 months after. Method of measurement: Frequency | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactJavad Sanchooli
Mashhad University of Medical Sciences
Outcome results
None listed